A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Inhibrx Biosciences, Inc
Wake Forest University Health Sciences
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tianjin Medical University Second Hospital
Chinese PLA General Hospital